AlphaStocks
6.2
Consider Buy

Bristol Myers Squibb Co (BMY)

As of Sep 20, 2026, Bristol Myers Squibb Co (BMY) scores 6.2/10 on AlphaStocks' five-model composite, #44 of 168 Health Care stocks. At $63, BMY trades 29% below its model fair value of $89.

Health Care / Pharmaceuticals

S&P 500

$63.03

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#44out of 168 in Health Care

Is BRISTOL MYERS SQUIBB CO a Good Investment in 2026?

BRISTOL MYERS SQUIBB CO (BMY) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates BRISTOL MYERS SQUIBB CO as Strong (8/9). However, the Graham model rates it Caution — Significantly above fair value. BRISTOL MYERS SQUIBB CO currently trades 29% below its estimated fair value of $89. BRISTOL MYERS SQUIBB CO ranks #44 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E18.2ROE38.1Market Cap129BDiv Yield4.3

Estimated Fair Value

$88.7329% below

Trading below estimated fair value. ROE of 38% signals strong profitability. P/E of 18x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Attractive

Earnings yield 6.6% · ROC 74%

Frequently Asked Questions

Is BRISTOL MYERS SQUIBB CO (BMY) a good investment?
As of Sep 20, 2026, Bristol Myers Squibb Co (BMY) scores 6.2/10 on AlphaStocks' five-model composite, #44 of 168 Health Care stocks. At $63, BMY trades 29% below its model fair value of $89. That is a middle-of-the-pack score with no strong signal either way.
What is BRISTOL MYERS SQUIBB CO's Piotroski F-Score?
BRISTOL MYERS SQUIBB CO's Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BMY overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $89, BMY appears undervalued. The stock currently trades 29% below its estimated fair value. Trading below estimated fair value. ROE of 38% signals strong profitability. P/E of 18x is moderate for this quality level.
How does BMY compare to other Health Care stocks?
BRISTOL MYERS SQUIBB CO ranks #44 out of 168 stocks in the Health Care sector, placing it in the top 26% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about BMY?
AlphaStocks evaluates BMY using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.2/10.

Similar Stocks

AMPHLLYACAD

Compare BMY with

AMPH vs BMYBMY vs LLYACAD vs BMYBMY vs FTI

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer